a2a ar Search Results


95
Chem Impex International buffer components
Buffer Components, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pm41753796-55-0-5?v=Chem+Impex+International
Average 95 stars, based on 1 article reviews
buffer components - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

90
Aderis Pharmaceuticals Inc a 2a ar agonist mre-0094
A 2a Ar Agonist Mre 0094, supplied by Aderis Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc03836209-279-15-32?v=Aderis+Pharmaceuticals+Inc
Average 90 stars, based on 1 article reviews
a 2a ar agonist mre-0094 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
GenScript corporation a 2a ar gene
A 2a Ar Gene, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc10070357-280-2-25?v=GenScript+corporation
Average 90 stars, based on 1 article reviews
a 2a ar gene - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Molsoft LLC a 2a ar, 3eml w3_opt
A 2a Ar, 3eml W3 Opt, supplied by Molsoft LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc02826142-112-9-32?v=Molsoft+LLC
Average 90 stars, based on 1 article reviews
a 2a ar, 3eml w3_opt - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Heptares Therapeutics Ltd a 2a ar complexes
A. Structures of selected AR ligands discussed in the text, including those that have <t>been</t> <t>co-crystallized</t> with the A <t>2A</t> AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24
A 2a Ar Complexes, supplied by Heptares Therapeutics Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc03701956-102-4-10?v=Heptares+Therapeutics+Ltd
Average 90 stars, based on 1 article reviews
a 2a ar complexes - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
AstraZeneca ltd oral a 2a ar antagonist ( k i value of)
A. Structures of selected AR ligands discussed in the text, including those that have <t>been</t> <t>co-crystallized</t> with the A <t>2A</t> AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24
Oral A 2a Ar Antagonist ( K I Value Of), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc12171953-66-18-6?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
oral a 2a ar antagonist ( k i value of) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Merck KGaA anti-a 2a ar
A. Structures of selected AR ligands discussed in the text, including those that have <t>been</t> <t>co-crystallized</t> with the A <t>2A</t> AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24
Anti A 2a Ar, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc03646121-52-5-10?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
anti-a 2a ar - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
BioGrammatics plasmids containing a 2a ar
A. Structures of selected AR ligands discussed in the text, including those that have <t>been</t> <t>co-crystallized</t> with the A <t>2A</t> AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24
Plasmids Containing A 2a Ar, supplied by BioGrammatics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pmc09882065-161-0-14?v=BioGrammatics
Average 90 stars, based on 1 article reviews
plasmids containing a 2a ar - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
DNAFORM Inc mouse a2a-adrenergic receptor (ar) clone
A. Structures of selected AR ligands discussed in the text, including those that have <t>been</t> <t>co-crystallized</t> with the A <t>2A</t> AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24
Mouse A2a Adrenergic Receptor (Ar) Clone, supplied by DNAFORM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a2a+ar/pm25843795-43-0-8?v=DNAFORM+Inc
Average 90 stars, based on 1 article reviews
mouse a2a-adrenergic receptor (ar) clone - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier



Image Search Results


A. Structures of selected AR ligands discussed in the text, including those that have been co-crystallized with the A 2A AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24

Journal: Journal of medicinal chemistry

Article Title: 2012 Philip S. Portoghese Medicinal Chemistry Lectureship: Structure-Based Approaches to Ligands for G Protein-Coupled Adenosine and P2Y Receptors, From Small Molecules to Nanoconjugates +

doi: 10.1021/jm400422s

Figure Lengend Snippet: A. Structures of selected AR ligands discussed in the text, including those that have been co-crystallized with the A 2A AR ( 1 , 2 , 5 , and 6 ). Dashed lines indicated the major H-bonding and π-bonding contacts between the receptor and ligand present in X-ray structures. Other ligands shown include pharmacological probes ( 4 and 9–12 ) and: advanced clinical candidates 3a and 3b for Parkinson’s disease; diagnostic agents for myocardial perfusion imaging 7 (approved and in trials for sickle cell anemia and ischemic conditions) and 8 (clinical candidate). B. The helical bundle of Family A GPCRs defines a cavity for the recognition of diverse ligands. The phospholipid bilayer is not shown. Figure courtesy of Stefano Costanzi (American Univ., Washington, DC). C. Historical progression of knowledge of the AR binding site(s). 19 , 20 , 37 , 39 , 41 , 45 Arrows in upper panels indicate the following interactions: Yellow, position of terminal amino group intended for covalent linking 37 ; orange, H-bonding interaction predicted between the exocyclic amine of adenine and a conserved Asn6.55 39 ; white, proximity of 3′ and 2′-hydroxyl groups with conserved His7.43 predicted using a neoceptor approach 41 . Lower panels: left, predicted docking of agonist 5 using the antagonist-bound X-ray structure 19 , 45 ; right, actual position of agonist 6 in X-ray structure. 20 , 24

Article Snippet: 19 , 20 A 2A AR complexes were crystallized by Heptares Therapeutics using receptors that are thermostabilized by systematic scanning mutagenesis (StaRs) include several other agonists and antagonists, including one with the antagonist 8-[4-[[[[(2-aminoethyl)amino]carbonyl]methyl)oxy]phenyl]-1,3-dipropylxanthine 2 (xanthine amine congener, XAC).

Techniques: Diagnostic Assay, Imaging, Binding Assay